# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: modern shifted

## Reason for visit

New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent. **S**

## Historical basis

- Alan Mathison Turing was born on 23 June 1912 in a nursing home in Paddington, London. **D**
- He was a long-distance runner: he built his strength in cross-country running, was known for running to scientific meetings, and in 1951 was still training for long-distance running on the roads around Wilmslow, where he had bought his first house. **D**
- After reporting a burglary at his home in 1952 he was arrested over a relationship with another man and tried on 31 March 1952 for "gross indecency"; rather than go to prison he accepted, for a year, oestrogen treatment intended to neutralise his libido. **D**
- His biographer Andrew Hodges writes that the drug was probably stilboestrol, a synthetic oestrogen; the 2009 government statement and other sources describe the treatment as a series of injections of female hormones. **D**
- Hodges describes the injurious and humiliating effect of the hormones on his body; it is often repeated that the treatment made him grow breasts, though he is known to have mentioned this only once. **D**
- In a letter of 23 November 1952 he wrote that he had decided to have "another, and rather more co-operative go at a psychiatrist"; this was Jungian analysis with a refugee analyst, and he became very enthusiastic about it and wrote down all his dreams. **D**
- His conviction led to the removal of his security clearance, so that he could no longer work for Government Communications Headquarters as he had since the war. **D**
- After the trial he returned to a wide range of academic work, including morphogenesis, quantum theory, and relativity, at Manchester University. **D**
- The roster lists depression as a primary condition; the sources read document his prosecution, the hormone treatment, and his decision to seek Jungian analysis, but record no diagnosis of depression, so a depressive illness is a retrospective interpretation. **R**

5 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Breasts enlarged and tender after a year of estrogen injections he was made to accept; finds it humiliating and has stopped changing in front of other runners. **S**
- Low mood, poor sleep, low libido, and loss of interest since the prosecution and the hormone course; wants to know whether his body will return to normal, and wants no treatment he has not agreed to. **S**

## Strengths and supports

- Supports: absorbing research work, running, a few trusted friends, and a willingness to talk to a therapist; no firearms in the home **S**

## Medications and allergies

- Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 31 March 1952: Year of oestrogen treatment (probably stilboestrol) accepted as the alternative to prison after his conviction for gross indecency **D** (CLM-0003, CLM-0004)
- 1952: Breast growth attributed to the hormone treatment, which he is known to have mentioned once **D** (CLM-0005)
- November 1952: Decided to see a psychiatrist again and began Jungian analysis **D** (CLM-0006)

## Procedures and immunizations

- No procedures before this visit. **S**
- 2025-10-14: Influenza vaccine, 2025-2026 season **S**
- 2021-05-11: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

PHQ-9: 15; GAD-7: 8; AUDIT-C: 2; Total testosterone: 112 ng/dL (low); Estradiol: 148 pg/mL (high); LH: 0.3 m[IU]/mL (low); FSH: 0.4 m[IU]/mL (low); SHBG: 88 nmol/L (high); Prolactin: 21.6 ng/mL (high); hCG (beta subunit): 1 m[IU]/mL; AFP: 2.6 ng/mL; ALT: 22 U/L; AST: 24 U/L; Total bilirubin: 0.6 mg/dL; Creatinine: 0.96 mg/dL; eGFR: 102 mL/min/1.73 m²; TSH: 1.9 mIU/L; Hemoglobin: 13 g/dL (low); 25-hydroxyvitamin D: 22 ng/mL (low). All results are synthetic.

BP 122/76 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 71.4 kg; BMI 22.5 kg/m². All vital signs are synthetic.

## Examination

Mental status: Tall, lean, casually dressed; slightly hesitant speech that becomes quick and precise on technical subjects; wry humor; cooperative; Mood "flattened, and angry about what was done to me"; affect constricted, reactive; thought process linear; no suicidal ideation, intent, or plan; no psychotic features; insight and judgment good. Functional status: At intake, working full days but sleeping badly, avoiding the running club changing room, and seeing friends less. Physical examination is intentionally limited. **S**

## Safety assessment

Current ideation: absent; intent: absent; plan: absent; access reviewed: yes. Disposition: Outpatient care with a collaborative safety plan, the 988 Suicide & Crisis Lifeline, and a two-week follow-up. This is synthetic and does not convert historical behavior into a current finding. **S**

## Assessment

1. Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment; status draft. **S**
2. Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue; status draft. **S**
3. Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment; status draft. **S**
4. Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime); status draft. **S**
5. Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL); status draft. **S**

## Plan

- Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be given. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocal. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgery. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles him. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018) **S**
- Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurs. Guideline: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012) **S**
- Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weeks. Guideline: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**
- Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recovers. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021); Sexually Transmitted Infections Treatment Guidelines: Men Who Have Sex with Men (2021); Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis (2023) **S**
- Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicated. Guideline: APA Guidelines for Psychological Practice With Sexual Minority Persons (2021) **S**

## Guideline basis

- EAA clinical practice guidelines: gynecomastia evaluation and management (2019), European Academy of Andrology
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018), Endocrine Society
- Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012), Endocrine Society
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- APA Guidelines for Psychological Practice With Sexual Minority Persons (2021), American Psychological Association
- Sexually Transmitted Infections Treatment Guidelines: Men Who Have Sex with Men (2021), Centers for Disease Control and Prevention
- Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis (2023), U.S. Preventive Services Task Force
